Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to 70.0%.

  • Vanda Pharmaceuticals' EBITDA Margin fell 511600.0% to 70.0% in Q4 2025 from the same period last year, while for Dec 2025 it was 69.44%, marking a year-over-year decrease of 494400.0%. This contributed to the annual value of 69.44% for FY2025, which is 494400.0% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported EBITDA Margin of 70.0% as of Q4 2025, which was down 511600.0% from 55.07% recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EBITDA Margin ranged from a high of 18.72% in Q2 2021 and a low of 81.53% during Q1 2025
  • For the 5-year period, Vanda Pharmaceuticals' EBITDA Margin averaged around 15.8%, with its median value being 13.57% (2022).
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 166600bps in 2021, then plummeted by -625000bps in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' EBITDA Margin (Quarter) stood at 13.25% in 2021, then dropped by -19bps to 10.72% in 2022, then plummeted by -242bps to 15.22% in 2023, then dropped by -24bps to 18.83% in 2024, then crashed by -272bps to 70.0% in 2025.
  • Its EBITDA Margin was 70.0% in Q4 2025, compared to 55.07% in Q3 2025 and 72.71% in Q2 2025.